BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9045338)

  • 21. Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
    Schena M; Barone C; Birocco N; Dongiovanni D; Numico G; Colantonio I; Bertetto O
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):271-6. PubMed ID: 15592837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction chemotherapy in the management of squamous cell cancer of the head and neck.
    Posner MR; Colevas AD
    Cancer J Sci Am; 1997; 3(2):73-5. PubMed ID: 9099455
    [No Abstract]   [Full Text] [Related]  

  • 23. Paclitaxel in the treatment of esophageal cancer.
    Weiner LM
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):106-8. PubMed ID: 10190790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer.
    Hitt R; Hornedo J; Colomer R; Hidalgo M; Brandariz A; Peña M; Vicent JA; Cortés-Funes H
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-58-S2-64. PubMed ID: 9045339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin.
    Flood W; Lee DJ; Trotti A; Spencer S; Murphy B; Khuri F; DeConti R; Wheeler R; Forastiere AA
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):64-9. PubMed ID: 10210542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemoradiotherapy in unresectable squamous cell head and neck cancer.
    Blot E; Staub E
    J Clin Oncol; 2003 Oct; 21(20):3887; author reply 3887-8. PubMed ID: 14551314
    [No Abstract]   [Full Text] [Related]  

  • 27. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I trial of radiotherapy and simultaneous 24-hour paclitaxel in patients with locally advanced head and neck squamous cell carcinoma.
    Steinberg L; Hassan M; Olmsted L; Sharan V; Stepnick D; Hoppel C; Mugharbil A; Subramanyan S; McGloin B; Mackay W; Strauss M
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-51-S19-56. PubMed ID: 9427267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer.
    Hitt R; Paz-Ares L; Hidalgo M; Colomer R; Brandariz A; Peña M; Alvarez-Vicent J; Hornedo J; Cortés-Funes H
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-20-S19-24. PubMed ID: 9427260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck.
    Wang TF; Chu SC; Kao RH; Yao CY; Li CC
    Jpn J Clin Oncol; 2008 Jul; 38(7):459-63. PubMed ID: 18586668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
    Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
    Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
    Argiris A; Li Y; Murphy BA; Langer CJ; Forastiere AA
    J Clin Oncol; 2004 Jan; 22(2):262-8. PubMed ID: 14722034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
    Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
    Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
    Hitt R; Jimeno A; Millán JM; Castellano D; Cortés-Funes H
    Cancer; 2004 Aug; 101(4):768-75. PubMed ID: 15305408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Second-line chemotherapy in head and neck cancer: what should we expect?
    Büntzel J; Micke O
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):269-73. PubMed ID: 19275504
    [No Abstract]   [Full Text] [Related]  

  • 36. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
    Rosen FR; Haraf DJ; Kies MS; Stenson K; Portugal L; List MA; Brockstein BE; Mittal BB; Rademaker AW; Witt ME; Pelzer H; Weichselbaum RR; Vokes EE
    Clin Cancer Res; 2003 May; 9(5):1689-97. PubMed ID: 12738722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm.
    Arnold SM; Regine WF; Ahmed MM; Valentino J; Spring P; Kudrimoti M; Kenady D; Desimone P; Mohiuddin M
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1411-7. PubMed ID: 15050317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer.
    Ferrari D; Fiore J; Codecà C; Di Maria G; Bozzoni S; Bordin V; Caldiera S; Luciani A; Zonato S; Floriani I; Foa P
    Anticancer Drugs; 2009 Mar; 20(3):185-90. PubMed ID: 19396017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study.
    Chougule PB; Akhtar MS; Akerley W; Ready N; Safran H; McRae R; Nigri P; Bellino J; Koness J; Radie-Keane K; Wanebo H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):58-63. PubMed ID: 10210541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrating novel agents into the curative treatment of head and neck cancer.
    Haddad R; Allen A; Wirth L; Tishler R; Posner M
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):157-9. PubMed ID: 16445367
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.